Mon, May 19, 9:02 PM (35 days ago)
**EYENOVIA, INC. (EYEN) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $14.720K (Q1 2024: $4.993K) - **Gross Profit:** $14.672K (Q1 2024: -$198.034K) - **Operating Expenses:** $3.045M (Q1 2024: $10.069M) - **Research & Development:** $673.043K (Q1 2024: $4.432M) - **General & Administrative:** $2.372M (Q1 2024: $3.637M) - **Net Loss:** $3.484M (Q1 2024: $10.922M) - **Net Loss Per Share:** -$1.59 (Q1 2024: -$18.75) - **Cash & Cash Equivalents:** $3.935M (Q1 2024: $2.121M) **Profit Margins:** - **Gross Margin:** 99.7% (Q1 2024: -3967.3%) - **Operating Margin:** -206.3% (Q1 2024: -978.8%) **Cash Flow:** - **Net Cash Used in Operating Activities:** -$4.443M (Q1 2024: -$9.892M) - **Net Cash Provided by Financing Activities:** $6.256M (Q1 2024: $3.133M) **Earnings Changes & Trends:** - **Revenue Growth:** 195.4% YoY - **Net Loss Decrease:** 68.6% YoY - **Operating Expenses Decrease:** 69.9% YoY **Quarterly Performance Discussion:** - **Revenue Growth:** Driven by sales of clobetasol propionate. - **Expense Reduction:** Due to restructuring, minimized expenses, and layoffs. - **Cash Flow:** Improved due to financing activities, including an "at-the-market" offering and induced exercise of stock warrants. **Uncertainties & Future Operations:** - **Going Concern:** Substantial doubt about the ability to continue as a going concern. - **Strategic Options:** Exploring strategic alternatives, including a potential reverse merger with Betaliq, Inc. - **Regulatory:** Awaiting regulatory approval for Optejet UFD in the U.S. - **Listing:** At risk of delisting from Nasdaq due to low stockholders' equity. - **Tariffs:** Potential negative impact on supply chain and product costs. **Future Impact:** - **Revenue Growth:** Dependent on successful commercialization of FDA-approved products and regulatory approval of Optejet UFD. - **Expense Management:** Continued focus on cost reduction and efficient use of resources. - **Cash Flow:** Dependent on successful financing activities and strategic transactions.